Epstein-Barrvirus (EBV)は1964年 にアフリカのバー キットリンパ腫培養細胞から発見された.そ の後,上 咽頭 がんや 胃がんなどとの関わ りも明らかにされ,歴 史的に最 も活発 に研究 がな されて きた ヒ トがん ウイルスhuman Cancer virusで あると言える.そ の明 らかな発癌 との関連 にも関わらず,EBVは 高度に普遍的なウイルスで もある. EBVは 主に唾液 を関した母子感染によって伝播 されると 考えられる.わ が国の25歳 以上の成人人口においては,ほ ぼ100%に 近い感染率を示す とされる. EBVと 血 液 リ ンパ 系 疾 患 との 関 わ りは 深 い.表1に, 主 なEBV関 連 血 液 リ ンパ 系 疾 患 を示 す.知 られ る 限 り リ ンパ 系 疾 患 が 主 体 で あ り,顆 粒 球 系 な ど他 ...

Kaposi sarcoma-associated herpesvirus (KSHV) is known to be associated with 3 distinct lymphoproliferative disorders: primary effusion lymphoma (PEL), multicentric Castleman disease (MCD), and MCD-associated plasmablastic lymphoma. We report 3 cases of a previously undescribed KSHV-associated lymphoproliferative disorder. The disease presented as localized lymphadenopathy and showed a favorable...

Karunatilake and Pidcock [1] recently described an interesting patient with autoimmune manifestations, cytopenias and lymphoproliferation. However, the authors did not comment on several important aspects. Did the patient have any lymphadenopathy, and was there a family history of a similar condition? Was the presence of double negative T cells in the peripheral blood looked for, was an aptotos...

Introduction: Castleman's disease is a rare lymphoproliferative disorder which may be confused with other causes of lymphadenopathy. Case Report: Here we report a case of unicentric Castleman's disease presenting with cervical lymphadenopathy. The patient was treated with complete surgical excision of lesion and was disease free at the time of reporting this article. This case has been reported...

Posttransplant lymphoproliferative disorder (PTLD) is a well-documented complication that arises as a result of immunosuppression in the setting of solid organ or bone marrow transplantation. The disorder may be subtle and/or extranodal. We report a patient with extranodal lymphoma following kidney transplantation who had successful treatment with surgery and chemotherapy.

We have used recombinant human erythropoietin (rHuEPO) in a phase 1/11 clinical trial to evaluate its ability to reverse refractory anemia in hematologic disorders. rHuEPO was administered subcutaneously 5 days per week at escalating doses (50 t o 150 U/kg per day). The aim of treatment was a hemoglobin (Hb) level 2 10 g/dL without blood transfusion. Of 25 patients treated, 17 were evaluable, m...

We have used recombinant human erythropoietin (rHuEPO) in a phase 1/11 clinical trial to evaluate its ability to reverse refractory anemia in hematologic disorders. rHuEPO was administered subcutaneously 5 days per week at escalating doses (50 t o 150 U/kg per day). The aim of treatment was a hemoglobin (Hb) level 2 10 g/dL without blood transfusion. Of 25 patients treated, 17 were evaluable, m...

OBJECTIVES CD30(+) lymphoproliferative disorder is a rare variant of cutaneous T-cell lymphoma. Sustained complete response following first-line treatments is rare. This retrospective review evaluates the response of refractory or recurrent lesions to palliative radiation therapy. METHODS The records of 6 patients with 12 lesions, treated with radiation therapy, were reviewed. All patients re...

Post-transplant lymphoproliferative disorder is characterized by the outgrowth of EBV-infected B cell lymphomas in immunosuppressed transplant recipients. Using a panel of EBV-infected spontaneous lymphoblastoid cell lines (SLCL) derived from post-transplant lymphoproliferative disorder patients, we assessed the sensitivity of such lymphomas to Fas-mediated cell death. Treatment with either an ...

Posttransplant lymphoproliferative disorder (PTLD) is a potentially fatal complication of solid organ transplantation. The majority of PTLD is of B-cell origin, and 90% are associated with the Epstein-Barr virus (EBV). Lymphomatoid granulomatosis (LG) is a rare, EBV-associated systemic angiodestructive lymphoproliferative disorder, which has rarely been described in patients with renal transpla...